comparemela.com

Latest Breaking News On - Ankit mahadevia - Page 6 : comparemela.com

Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update

10.08.2022 - Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022 Initiation of a Phase 2 Cross-indication Resistant Pathogen Trial of SPR206 Expected in 3Q 2023 Continued .

United statesUnited kingdomTed jenkinsAnkit mahadeviaNational institute of allergyDepartment of defensePfizer incDepartment of healthTebipenem hbr researchSpero therapeutics incEuropean congressWarfighter medical research program under award noNational institutes of healthBiomedical advanced researchHuman servicesCongress engagement

FDA Needs More Data on Tebipenem HBr for Complicated UTI

The FDA has issued a Complete Response Letter regarding the New Drug Application for tebipenem HBr for complicated urinary tract infections.

Ankit mahadeviaDrug administrationComplete response letterSpero therapeuticsNew drug applicationPriority review

FDA Needs More Data on Tebipenem HBr for Complicated UTI

The FDA has issued a Complete Response Letter regarding the New Drug Application for tebipenem HBr for complicated urinary tract infections.

Ankit mahadeviaDrug administrationComplete response letterSpero therapeuticsNew drug applicationPriority review

Spero Therapeutics (SPRO) Receives CRL from U S Food and Drug Administration for Tebipenem HBr New Drug Application

Spero Therapeutics (SPRO) Receives CRL from U S Food and Drug Administration for Tebipenem HBr New Drug Application
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ankit mahadeviaBiomedical advanced researchHuman servicesTebipenem hbr research supportselectDrug administrationDevelopment authorityDepartment of healthOffice of theSpero therapeutics incComplete response letterNew drug applicationPrescription drug user fee actChief executive officerResearch supportselectAssistant secretary

Spero Therapeutics, Inc (SPRO) CEO Ankit Mahadevia on Q1 2022 Results - Earnings Call Transcript

Spero Therapeutics, Inc. (NASDAQ:NASDAQ:SPRO) Q1 2022 Earnings Conference Call May 16, 2022 04:30 PM ET Company Participants Ted Jenkins - Vice President-Investor Relations Ankit Mahadevia.

Esther hongKevin degeeterAnkit mahadeviaRam selvarajuElaine kimLouise chenTed jenkinsSath shuklaDavid melnickCompany participantsNational institute of allergiesDepartment of defenseSpero therapeutics incSpero therapeuticsConference call maySpero therapeutics first quarter

vimarsana © 2020. All Rights Reserved.